Stockscreener 앱 받기
0.0004
300.00%
0.0003
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Form S-1/A Virpax Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Nigeria
Price to earnings forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to EBITDA forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to book forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to sales forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to revenue forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax Pharmaceuticals, Inc. Actuals & Estimates (OTC:VRPX) - TradingView
Form S-1/A Virpax Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Nigeria
Top Players and Market Competition in the Non-Opioid Pain Patch Industry - openPR.com
VRPX Stock Plummets 95.5% in Pre-Market Trading on NASDAQ - Meyka
Virpax Pharmaceuticals, Inc. (VRPX) - Minichart
Virpax Pharmaceuticals (VRPX) Expected to Announce Earnings on Tuesday - Defense World
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
VRPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World
Revenue per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
Virpax reports positive study results for pain management drug - MSN
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
Virpax Pharmaceuticals to conduct reverse stock split - Intellectia AI
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Curanex Pharmaceuticals Shares Fall in Nasdaq Debut - marketscreener.com
Vinay Shah Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
ENSCW Stock Price, News & Analysis - Stock Titan
BTAX Stock Price, News & Analysis - Stock Titan
QBIO Stock Price, News & Analysis - Stock Titan
EVLO Stock Price, News & Analysis - Stock Titan
PXMD Stock Price, News & Analysis - Stock Titan
XSNX Stock Price, News & Analysis - Stock Titan
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com UK
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - FinancialContent
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Nigeria
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
User - The Chronicle-Journal
Virpax Pharmaceuticals granted Nasdaq listing extension - Investing.com
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com Nigeria
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Star Tribune - FinancialContent
ADM’s multiple accounting errors and SEC probe are ‘highly concerning’ to investors - Fortune
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - citybiz
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk - TipRanks
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - The Chronicle-Journal
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - The Chronicle-Journal
Virpax Regains Compliance with Nasdaq Minimum Bid Price - Business Wire
Maxim Group Upgrades Virpax Pharmaceuticals(VRPX.US) to Buy Rating, Announces Target Price $3 - Moomoo
These stocks have an unusual volume in today's session - ChartMill
What's going on in today's after hours session - ChartMill
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing - citybiz
Virpax Pharmaceuticals, Inc. - MLQ.ai
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention - The Chronicle-Journal
Acute Pain Pipeline Drugs Analysis Report, 2024: FDA Approvals, - openPR.com
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments - The Chronicle-Journal
Virpax Pharmaceuticals Reports 2023 Year-End Results - The Chronicle-Journal
Scilex reaches settlement in Sorrento bankruptcy case - Investing.com
Highest-Paid CEOs - AFL-CIO
0.74%
3.77%
자본화:
|
볼륨(24시간):